Refractory Non-Hodgkin Lymphoma Clinical Trials in Chicago, Illinois

3 studies are recruiting for refractory non-hodgkin lymphoma in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

    This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may hel…

    Stage
    Phase 1
    Ages
    1 to 30
    Site
    Lurie Children's Hospital-Chicago, Chicago, Illinois
    Locations
    21 in total
    Run by
    Children's Oncology Group

    See if you can join NCT04851119 on ClinicalTrials.gov

  2. A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

    This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of Chicago, Chicago, Illinois
    Locations
    36 in total
    Run by
    Lyell Immunopharma, Inc.

    See if you can join NCT07188558 on ClinicalTrials.gov

  3. Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

    This phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a CAR-T therapy) and find out what effect, if any, it has on treating patients with HIV-associated aggressive B-cell non-Hodgkin lymphoma that has come back (relapsed) or not responded to treatment (refractory)…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Illinois at Chicago, Chicago, Illinois
    Locations
    7 in total
    Run by
    AIDS Malignancy Consortium

    See if you can join NCT05077527 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.